Syncom Formulations (India) Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 20.2%)
- Efficient capital deployment (ROCE 26.8%)
- Attractively valued vs sector (P/E 22.6x vs industry 54.7x)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SYNCOMF · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% |
| FII | — | 0.08% | 0.09% | 0.10% | 0.13% | 0.11% |
| Public | 49.44% | 49.35% | 49.34% | 49.34% | 49.30% | 49.32% |
Latest News
All newsSyncom Formulations publishes newspaper notice
*Syncom Formulations publishes newspaper notice.* This is a routine compliance disclosure filed with the exchange. The company has shared a copy of its newspaper publication as part of regulatory requirements. No financial or operational impact is indicated. 📊 *STOCKS:* $SYNCOMFOR | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Syncom Formulation P/E forward ratio data released
*Syncom Formulation P/E forward ratio data released.* The forward price-to-earnings ratio for Syncom Formulation (India) Ltd. has been updated on TradingView, reflecting market expectations. While no fundamental change in operations is indicated, the valuation metric may influence short-term trading sentiment. Traders may assess the stock against sector peers with average P/E around **28x**. 📊 *STOCKS:* SYNCOMF | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Valuation
Syncom Formulations attracts investor attention on NSE
*Syncom Formulations attracts investor attention on NSE* due to increased retail interest and positive sentiment. The stock has seen a **15% rise** in the past week, outperforming sector benchmarks. Trading volumes surged to **2.3x** average, indicating momentum buildup. Fundamentally, it remains a small-cap with moderate revenue growth. 📊 *STOCKS:* SYNCOMF | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Syncom Formulations attracts investor attention amid growing market speculation
*Syncom Formulations attracts investor attention amid growing market speculation.* The stock has seen increased retail participation due to its low share price and high volatility. Traders are eyeing potential breakout patterns despite limited institutional holding. No major corporate announcements or financial updates were disclosed recently. 📊 *STOCKS:* SYNCOMF | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #smallcap